Document:

Exhibit 4.3

                    FIRST AMENDMENT TO DISTRIBUTION AGREEMENT

This First Amendment to Distribution Agreement (the "First Amendment") is made
and entered into as of October 23, 2001 (the "Effective Date") by and between
Century Medical, Inc., a corporation duly organized and existing under the laws
of Japan with its principal place of business located at 1-6-4 Ohsaki,
Shinagawa-Ku, Tokyo, 141-8588, Japan ("DISTRIBUTOR"), and EP MedSystems, Inc., a
New Jersey corporation with its principal place of business located at 100
Stierli Court, Suite 107, Mount Arlington, New Jersey 07856 USA ("COMPANY").

                                 R E C I T A L S

DISTRIBUTOR and COMPANY have entered into that certain Distribution Agreement
effective as of July 16, 1997 (the "Distribution Agreement") pursuant to which
COMPANY appointed DISTRIBUTOR as its exclusive distributor of certain products
of COMPANY within the Territory.

DISTRIBUTOR and COMPANY desire to amend certain provisions contained in the
Distribution Agreement.

      NOW, THEREFORE, in consideration of the mutual covenants and undertakings
contained herein, and other good and valuable consideration, the receipt and
sufficiency of which are hereby acknowledged, and subject to and on the terms
and conditions herein set forth, the parties hereto agree as follows:

A.    Definitions. Unless otherwise defined herein, all capitalized terms in
      this Amendment shall have the respective meanings ascribed to them in the
      Distribution Agreement.

B.    Amendment to Definitions. The first sentence of Section 1.2 Products shall
      be deleted in whole and replaced with the following:

      "Products" shall mean COMPANY's current line of (1) EP Workmate(TM)
      electrophysiology recording systems and EP-3 computerized cardiac
      simulator; (2) Alert(TM) Companion, Alert PA/TD catheters, Alert RA/CA
      catheters, ViewMate(TM), ViewMate catheters, EP-4 cardiac stimulators; and
      (3) SilverFlex(TM) diagnostic catheters, conventional diagnostic catheters
      and Focal Recorder catheter ("Product Category (B)"), as listed in
      Schedule 1, as amended from time to time together with all line
      extensions, modifications and improvements thereto.

C.    Amendment of Term. Section 3 shall be deleted in whole and replaced with
      the following:

      3. Term of Distributorship. This Agreement and the rights and obligations
      conferred on DISTRIBUTOR and COMPANY hereunder shall come into effect on
      the date mentioned in the preamble hereto (or with respect to Products
      added by the First Amendment, on the date

                                Ex.4.3 - Page 1
<PAGE>

      of said First Amendment) and shall remain in effect for a period of five
      (5) years from the date on which DISTRIBUTOR has obtained both (a) the
      import license (Shonin) for the Alert Companion, Alert PA/TD and RA/CA
      catheters, ViewMate and ViewMate catheter Products and (b) the
      reimbursement approval for the Alert PA/TD, Alert RA/CA and ViewMate
      catheter Products from the Japanese Ministry of Health, Labor and Welfare
      (the "MHLW"), as amended, unless terminated, canceled, or renewed in
      accordance with provisions of this Agreement. Notwithstanding the
      foregoing, DISTRIBUTOR shall not be obligated to sell, distribute, market
      or promote to sell any Product in the Product Category (B) prior to
      January 1, 2003 (the "Category (B) Effective Date").

D.    Amendment of DISTRIBUTOR Duties.

      1.    Section 4.1(v) shall be deleted in whole and replaced with the
            following:

                  4.1(v) not to solicit the sale of, promote the sale of, sell,
            exhibit for sale, distribute or manufacture any product directly
            competitive with the Products; provided, however that the
            restrictions in this subsection (v) shall not apply to diagnostic
            catheter products of other manufacturers, that do not have internal
            cardio-version capabilities.

      2.    Section 4.1(vi) shall be deleted in whole and replaced with the
            following:

                  4.1(vi) to be responsible for obtaining, at its own expense,
            all necessary medical device product approvals ("Shonin") from the
            MHLW and to conduct, when necessary, any clinical trials needed to
            obtain a Shonin to market the Products in the Territory. Prior to
            DISTRIBUTOR actually conducting a clinical trial for any Product,
            DISTRIBUTOR and COMPANY shall discuss in good faith taking into
            consideration final commercial Product availability, IDE status of
            the Products in the USA, the availability and feasibility of using
            IDE data for a Shonin application and other such factors that may
            affect filing of a Shonin application with the MHLW.

      3.    The original Section 4.1(vii) shall be renumbered as Section
            4.1(viii), and a new Section 4.1(vii) shall be added as follows:

                  4.1(vii) to keep COMPANY informed of regulatory requirements
            in the Territory and to, from time to time, provide COMPANY with
            updated amendments to the Memorandum of Compliance to be executed by
            the parties in the form attached hereto as Schedule 3.

D.    Amendment of Duties of COMPANY.

      1.    Section 5.1(i) shall have added to it two new sentences as follows:

            COMPANY shall further develop its catheter Product line to include a
            5 French (5Fr) line of catheters (that falls under the Product
            Category (B) in the definition of Products in

                                Ex.4.3 - Page 2
<PAGE>

            Section 1.2) to meet the reasonable needs of customers in the
            Territory. COMPANY shall use its best efforts to have available to
            DISTRIBUTOR such 5Fr catheters by no later than six months prior to
            the Category (B) Effective Date and provide all other information
            required for DISTRIBUTOR to obtain any Shonin required for the 5Fr
            catheters. In the event that the final products have not been made
            available for sale by DISTRIBUTOR in the Territory by the date
            mentioned above, DISTRIBUTOR shall have the option to terminate its
            obligations with respect to any and all products in the Product
            Category (B). COMPANY shall reasonably and in good faith discuss
            with DISTRIBUTOR the development, technologies, challenges and
            potential manufacture of a 4fr line of catheters taking into
            consideration the market needs and specification requirements of the
            Territory.

      2.    Section 5.1(iii) shall be deleted in whole and replaced with the
            following:

            5.1(iii) to provide DISTRIBUTOR with materials necessary to obtain
            and maintain the Shonin to import and sell the Products within the
            Territory by furnishing to DISTRIBUTOR, at COMPANY's cost, such
            technical descriptions, specifications, data, clinical data
            including but not limited to IDE, PMA and 510(k) documentation,
            drawings, information, service manuals, quality control audits,
            facility inspection reports issued by governmental regulators or
            international quality control auditors, and so forth regarding the
            Products, in the English language, as DISTRIBUTOR may reasonably
            request in order for DISTRIBUTOR to fulfill its obligations set
            forth in Section 4.1(vi). COMPANY shall provide DISTRIBUTOR with any
            Product necessary for DISTRIBUTOR to fulfill its obligations under
            Section 4.1(vi) at fifty percent (50%) of the normal transfer price
            which DISTRIBUTOR will pay for a commercial resale Product.

F.    Amendment of Sale of Product to DISTRIBUTOR.

      1.    Section 8.3 Acceptance and Cancellation of Orders. The following
            sentence shall be added as the third sentence:

            DISTRIBUTOR's purchase order(s) for Workmate Systems, Alert Systems,
            EP-3 and EP-4 stimulators shall allow for a thirty (30) day lead
            time from a date of order until shipment by COMPANY.

      2.    Section 8.6 Distributor Obligations & Minimum Purchases. Section 8.6
            shall be deleted in whole and replaced with the following:

            8.6 Distributor Obligations & Minimum Purchases.

            COMPANY and DISTRIBUTOR shall in good faith mutually agree upon the
            minimum purchase amounts expressed in U.S. Dollars for each calendar
            year during the term of this Agreement (the "Minimum Purchase
            Amounts") that reflect an acceptable performance

                                Ex.4.3 - Page 3
<PAGE>

            of Distributor under this Agreement, and such Minimum Purchase
            Amounts agreed by the parties shall be identified in Schedule 2,
            attached hereto, as supplemented from time to time. The Minimum
            Purchase Amounts for the calendar years 2001 and 2002 shall be as
            set forth in Schedule 2. The determination of the Minimum Purchase
            Amounts for each subsequent calendar year shall be made by no later
            than October 1 of each preceding year upon good faith negotiation by
            the parties. The premise from which COMPANY and DISTRIBUTOR shall
            enter each negotiation shall be increasing year over year sales
            caused by: (a) DISTRIBUTOR improving the COMPANY's market share
            position, (b) introduction of new Products in the Territory, and (c)
            pricing leverage; but taking into consideration DISTRIBUTOR's
            initial investment to obtain approvals for and develop the market
            for the Products, general market conditions in the Territory, and
            the competitive position and characteristics of the Products. The
            parties intend to preclude any revision or modification of the
            Minimum Purchase Amounts by any tribunal and thereby avoid any
            litigation or dispute over the reasonableness of these standards. If
            both parties cannot agree to the Minimum Purchase Amounts as
            provided herein, such disagreement shall be resolved by arbitration
            in accordance with Section 14.7 of this Agreement.

            In the event that DISTRIBUTOR fails to meet 80% of the Minimum
            Purchase Amounts agreed by the parties as shown in Schedule 2 hereto
            for any calendar year during the term of this Agreement, the
            COMPANY, at its sole option, may change DISTRIBUTOR'S status under
            this Agreement to non-exclusive and appoint other distributors to
            import and distribute the Products in the Territory. In the event
            that DISTRIBUTOR fails to meet 70% of the Minimum Purchase Amounts
            agreed by the parties as shown in Schedule 2 hereto for any calendar
            year during the term of this Agreement, the parties shall meet at a
            mutually agreed upon place and time to discuss remedying this
            situation.

            Subject to COMPANY fulfilling its obligations in Section 5.1(i)
            regarding a 5fr line of catheters and DISTRIBUTOR's receipt of the
            Shonin for the Alert System, after the Category (B) Effective Date
            and so long as DISTRIBUTOR is engaged in the sale of a line of
            standard fixed curve diagnostic catheters of a third party that is
            competing with diagnostic catheters of COMPANY, for each Alert
            catheter purchased by DISTRIBUTOR, DISTRIBUTOR shall be obligated to
            purchase one standard non-defibrillation diagnostic catheter
            (platinum electrode or SilverFlex(TM) electrode at DISTRIBUTOR's
            option) from COMPANY. DISTRIBUTOR and COMPANY shall reconcile this
            purchase obligation on quarterly basis in accordance with the
            following rules:

                  (a) if the number of COMPANY's non-defibrillation diagnostic
                  catheters purchased by DISTRIBUTOR in one quarter is less than
                  the number of the Alert catheters purchased by DISTRIBUTOR in
                  the same quarter, then DISTRIBUTOR shall place a make-good
                  order to reconcile the account in the following quarter; and

                                Ex.4.3 - Page 4
<PAGE>

                  (b) if the number of COMPANY's non-defibrillation diagnostic
                  catheters purchased by DISTRIBUTOR in one quarter is more than
                  the number of the Alert catheters purchased by DISTRIBUTOR in
                  the same quarter, then, DISTRIBUTOR may carry-forward a credit
                  to the following quarter.

G.    Schedule 1 is hereby amended as attached hereto, and the International
      Product Price List for all Products, as amended form time to time, is
      attached hereto as Schedule 1.

H.    Schedule 2 is hereby amended and shall be as attached hereto.

I.    No Other Changes. Except as amended by this First Amendment, the
      Distribution Agreement shall remain in full force and effect as originally
      stated and, all references to the Distribution Agreement shall henceforth
      refer to the Distribution Agreement as amended by this First Amendment.
      This Amendment, including all exhibits and schedules attached hereto,
      shall be deemed incorporated into, and a part of the Distribution
      Agreement.

J.    Conflicts. In the event of any conflict between the terms of the
      Distribution Agreement and the terms of this Amendment, the terms of this
      First Amendment will control.

      IN WITNESS WHEREOF, the parties have caused this First Amendment to be
executed as of the Effective Date.

EP MedSystems, Inc.

By: s/ David Jenkins

    David Jenkins,
    President and CEO

Century Medical, Inc.

By: s/ Yasuo Kyotani

    Yasuo Kyotani
    President and CEO

                                Ex.4.3 - Page 5
<PAGE>

                                   Schedule 1
                               Products and Prices

DESCRIPTION: All existing Products as defined in Section 1.2 together with all
line extensions, modifications and improvements thereto as described in the
attached, as amended from time to time.

Prices: Shall be as listed on COMPANY'S International Product Price List,
including the attached Alert System, EP Diagnostic Catheters and accessories
price list, in effect on the date on which COMPANY accepts an order less a
minimum discount of 20%. Pricing for the 5fr catheters and ViewMate(TM) probes
shall be determined at the time COMPANY confirms that 5fr catheters and ViewMate
probes are commercially available however in no event shall the price for 5fr
catheters exceed the price for 6fr catheters on the attached price sheet and
ViewMate probes shall have a target price, depending upon ultimate production
costs, of $1,000 per probe unless future models incorporate additional features
or technology, in which case, the cost to DISTRIBUTOR shall be no more than 80%
of COMPANY's USA list price. COMPANY may also offer additional discounts
depending on the competitiveness of individual Products or give special
consideration for additional volume discounting on a case by case basis.
Specifics to be mutually discussed by the parties and agreed upon at the time of
purchase.

      COMPANY shall on a case by case basis prepare price quotations for custom
made Products based upon DISTRIBUTOR'S specific inquiry, taking into
consideration expected purchase volumes.

                                Ex.4.3 - Page 6
<PAGE>

                                   Schedule 2
                            Minimum Annual Purchases

2001: U.S.$900,000
2002: U.S.$900,000

Note: The Minimum Purchase Amount for Year 2002 set forth above is a current
good faith estimate. COMPANY and DISTRIBUTOR agree to negotiate the actual
amount in good faith by the end of 2001, which amount shall reflect the results
of an investigation to be conducted in Japan by an engineer of COMPANY
(scheduled for October 2001) with respect to pending issues for EP Workmate,
including, without limitation, correction of Windows-bug and hardware
improvement.

                                Ex.4.3 - Page 7
<PAGE>

                                   Schedule 3
                            Memorandum of Compliance

In order to comply with the request from Century Medical, Inc. ("CMI"), we, EP
MedSystems, Inc. shall implement the following:

1.    QC Certificate

      Quality Control Certificate to be included in every shipment to CMI.

2.    Sterilization Validation Data

      Provide CMI with the most current and latest Sterilization Validation Data
      once a year.

3.    Certificate to Foreign Government and Standard Operating Procedure (SOP),
      etc.

      Provide CMI with the up-dated "Certificate to Foreign Government" issued
      by FDA relative to manufacturing plant or the copy of certificate
      certifying compliance to EN 46001. Provide CMI the following information
      at least once every two years for CMI to confirm that the product
      specification conforms to the contents of the Japanese Shonin document,
      copies of the up-dated version of product specification sheet, production
      flow chart, SOP of quality control testing protocol and other necessary
      document, and keep CMI update when these documents are amended or
      modified. Manufacturer further agrees to allow CMI personnel to visit
      manufacturer to actually confirm these points at the manufacturing plant
      when necessary.

4.    Advance Notice of Product Modifications and/or Improvements

      To keep CMI informed in writing regarding any and all modifications and/or
      improvements of the products, change in method of sterilization, change in
      packaging, change in facility or factory location and changes in test
      standards adequately prior to implementation of them.

5.    Facility Inspections, Product Recalls

      Promptly notify CMI of any actions taken with respect to manufacturer or
      the products by regulators in other jurisdictions, including (i) any
      facility inspection resulting in any notice of infraction, warning or
      other action, (ii) voluntary or mandatory recalls or withdrawal of
      products, (iii) administrative or court proceedings regarding the products
      and (iv) similar matters. Manufacturer will promptly provide CMI with
      copies of any correspondence with regulators regarding any of the
      foregoing.

6.    Transmitting information method and person responsible

      Concerning the case specified items 4and 5 above, notify the method of
      transmitting information and person responsible for transmission.
      Differently settle the detail of information method, address, phone, fax,
      e-mail, address of person in charge, and promptly inform them in case of
      change.

7.    Packaging

      Provide for the Products to be suitably packaged and packed for export.

8.    Product Complaint Handling

      Manufacturer further agrees to provide CMI with a written report of
      findings by manufacturer of any product complaint report submitted by CMI
      in a reasonably timely manner. Where a product complaint involves a
      product failure that resulted in bodily injury or death, manufacturer
      shall expedite and place the highest priority possible to investigate and
      report in writing manufacturer's findings to CMI.

COMPANY: _____________________________        CENTURY MEDICAL, INC.

Date: ________________________________        Date: ____________________________
Signature: ___________________________        Signature: _______________________
Name: ________________________________        Name: ____________________________
Title: _______________________________        Title: ___________________________
Company: _____________________________

                                Ex.4.3 - Page 8Exhibit 4.4

                       PREFERRED STOCK PURCHASE AGREEMENT

      PREFERRED STOCK PURCHASE AGREEMENT (this "Agreement") made as of the 23rd
day of October, 2001 by and among EP MEDSYSTEMS, INC. (the "Company") and
MEDTRONIC, INC. (the "Purchaser").

                                    RECITALS

      WHEREAS, the Purchaser desires to invest in the Company by purchasing and
acquiring shares of the Company's authorized but unissued Series A Preferred
Stock (as defined in Section 1.1); and

      WHEREAS, the Company desires to issue and sell shares of Preferred Stock
to the Purchaser upon the terms and conditions set forth herein; and

      WHEREAS, such purchase and sale is to be made in reliance upon such
exemption from the registration requirements of the Securities Act as may be
available with respect to the purchases of Preferred Shares (as defined in
Section 1.1) to be made hereunder;

      NOW, THEREFORE, in consideration of the mutual promises herein made, and
in consideration of the representations, warranties and covenants herein
contained, the parties hereto agree as follows:

      SECTION 11. SALE AND PURCHASE OF PREFERRED SHARES; CLOSING

            11.1 Subscription, Sale and Purchase of Preferred Shares.

                  (a) Upon the terms and subject to the conditions of this
Agreement, on the Closing Date (as hereinafter defined) the Company agrees to
issue, sell and deliver to the Purchaser, and the Purchaser agrees to purchase
and acquire from the Company, such number of shares of the Company's Series A
Convertible Preferred Stock, without par value per share (the "Series A
Preferred Stock") as shall have a value of U.S.$1.2 million (the "Purchase
Price"), which shall be determined by dividing the Purchase Price by the Market
Price (as hereinafter defined). For purposes of this Agreement, "Preferred
Shares" means the shares of Series A Preferred Stock purchased by the Purchaser
hereunder and "Market Price" means the average of the closing prices of the
Company's Common Stock (as hereinafter defined) for the ten days immediately
prior to the Closing Date.

                  (b) On or before the Closing Date, the Company shall have
adopted and filed with the Secretary of State of the State of New Jersey a
Certificate of Amendment to the Company's Certificate of Incorporation in
substantially the form attached as Exhibit A (the "Designation") setting forth
the rights, preferences, privileges and limitations of the Series A Preferred
Shares, which rights, preferences, privileges and designations shall include
that such Series A Preferred Shares shall be convertible under certain
circumstances into shares of Common Stock (as hereinafter defined) of the
Company on a one-for-one basis (subject to anti-

                                Ex.4.4 - Page 1
<PAGE>

dilution adjustments set forth therein) (such shares of Common Stock issued or
issuable upon the conversion of the Series A Preferred Stock being referred to
as "Conversion Shares").

            11.2 Closing.

                  (a) The closing of the issuance and sale of the Preferred
Shares to the Purchaser shall occur in such location and manner (i.e., by
telecopy exchange of signature pages with originals to follow by overnight
delivery) as the parties may mutually agree, subject to the terms and conditions
hereof. As used herein "Closing" shall mean the closing of the issuance and sale
of the Preferred Shares to the Purchaser and the "Closing Date" shall mean
October 23, 2001 provided that each of the conditions set forth in Sections 4
and 5 hereof.

                  (b) On the Closing Date, the parties shall exchange, by
facsimile transmission, this Agreement and the Registration Rights Agreement (as
contemplated under Section 4.8 hereof) (collectively, the "Transaction
Documents"), duly executed by each of them. The Company shall further deliver,
by facsimile transmission, the preferred stock purchase agreement entered into
by the Company and Century Medical, Inc. (as contemplated by Section 4.10
hereof)(the "Century Medical Agreement"). Upon receipt of the executed
Transaction Documents and the Century Medical Agreement, the Purchaser shall
initiate the delivery, by wire transfer to a bank in the United States specified
by the Company for the account of the Company, of immediately available funds,
in United States Dollars, in an amount equal to the Purchase Price which
Purchase Price shall be received in such account no later than the close of
business on October 26, 2001. Within three (3) business days after the receipt
of the Purchase Price, the Company shall deliver to the Purchaser a copy of the
Transaction Documents bearing original signatures, a copy of the fully-executed
Century Medical Agreement and a stock certificate or certificates representing
the Preferred Shares, duly executed by the Company, registered in the
Purchaser's name (or the name of its nominee), free of all restrictive and other
legends (other than the legend specified in Section 8.2 and otherwise in form
for good delivery).

      SECTION 12. REPRESENTATIONS AND WARRANTIES OF THE COMPANY

      The Company represents and warrants to the Purchaser as follows:

            12.1 Organization and Good Standing. The Company is a corporation
duly organized, validly existing and in good standing under the laws of the
State of New Jersey and has all requisite power and authority, and all necessary
licenses and permits, to own and lease its properties and assets and to conduct
its business as now conducted. Each subsidiary as referred to in the Company
Reports (as hereinafter defined) is a corporation duly organized, validly
existing and in good standing under the laws of the jurisdiction of its
incorporation and has all requisite power and authority, and all necessary
licenses and permits, to own and lease its properties and assets and to conduct
its business as now conducted. The Company and its subsidiaries are each
qualified to do business as a foreign corporation and are in good standing in
all states where the conduct of their respective businesses or their ownership
or leasing of property requires such qualification, except where the failure to
so qualify would not have a material adverse effect on the Company's and the
subsidiaries' business, properties, assets, operations or condition (financial
or otherwise), taken as a whole.

                                Ex.4.4 - Page 2
<PAGE>

            12.2 Authorization. The Company has all requisite power and
authority to execute and deliver this Agreement and each other agreement
required to be executed and delivered by it pursuant to this Agreement
(collectively, the "Company Agreements") and to carry out the transactions
contemplated hereby and thereby. The execution, delivery and performance by the
Company of this Agreement, and each other Company Agreement have been duly
authorized by all requisite corporate action, and this Agreement has been duly
executed and delivered by the Company and constitutes (and, when executed and
delivered against payment therefor as contemplated herein, each other Company
Agreement will constitute) the valid and binding obligation of the Company,
enforceable against the Company in accordance with their respective terms.

            12.3 No Conflict with Law or Documents. The execution, delivery and
performance of this Agreement or any Company Agreement by the Company, the
issuance of the Preferred Shares sold hereunder and of the Conversion Shares
issuable upon conversion of the Preferred Shares and the consummation by the
Company of the transactions contemplated hereby and thereby do not and will not
violate any provision of law, any rule or regulation of any governmental
authority, or any judgment, decree or order of any court binding on the Company
and, do not and will not conflict with or result in any material breach of any
of the terms, conditions or provisions of, or constitute a default under, or
result in the creation of any lien, security interest, charge or encumbrance
upon any of the properties, assets or outstanding stock of the Company under its
Certificate of Incorporation or By-Laws, or any material indenture, mortgage,
lease, agreement or other instrument to which the Company is a party or by which
it or any of its properties is bound (except for such conflicts, defaults,
terminations, amendments, accelerations, cancellations and violations under any
such indenture, mortgage, lease, agreement or other instrument as would not,
individually or in the aggregate, have a material adverse effect on the Company
and its subsidiaries' business, properties, assets, operations or condition
(financial or otherwise) taken as a whole).

            12.4 Capital Stock of Company.

                  (a) The authorized capital stock of the Company consists of:
(i) 5,000,000 shares of preferred stock of the Company, no par value per share,
of which no shares are issued and outstanding; and (ii) 25,000,000 shares of
common stock, no par value, $.00l stated value per share (the "Common Stock"),
of which 13,861,217 shares are issued and outstanding as of the date hereof and
all such outstanding shares are validly issued, fully paid and nonassessable and
were issued in accordance with the registration or qualification provisions of
the Securities Act and any relevant state securities laws, or pursuant to valid
exemptions therefrom, (iii) 1,000,000 shares of Common Stock reserved for
issuance pursuant to the Company's 1995 Long Term Incentive Plan, (iv) 360,000
shares of Common Stock reserved for issuance pursuant to the Company's 1995
Director Option Plan, and (v) 147,000 shares of Common Stock reserved for
issuance pursuant to existing non-plan stock options; of which with respect to
the 1995 Long Term Incentive Plan, the 1995 Director Option Plan and other
non-plan stock options, an aggregate of 1,291,008 options have been granted and
are outstanding as of December 31, 2000. A further 362,250 shares of Common
Stock are reserved for issuance pursuant to outstanding warrants issued under a
certain Common Stock and Warrant Purchase Agreement, dated as of August 31,
1999, as subsequently amended, a further 812,500 shares of Common Stock are
reserved for issuance pursuant to outstanding warrants issued under a certain

                                Ex.4.4 - Page 3
<PAGE>

Common Stock and Warrant Purchase Agreement, dated as of February 16, 2001, as
subsequently amended, and a further 100,000 shares of Common Stock are reserved
for issuance pursuant to outstanding warrants issued to an executive officer in
connection with his employment under Warrant, dated as of July 20, 2001.

            (b) There are no preemptive or similar rights to purchase or
otherwise acquire shares of capital stock of the Company pursuant to any
provision of law or the Certificate of Incorporation or By-Laws of the Company
or by agreement or otherwise. Except as set forth in this Section 2.4, there are
no outstanding subscriptions, warrants, options or other rights (including,
without limitation, conversion or preemptive rights) or commitments of any
character to subscribe for or purchase from the Company, or obligating the
Company to issue, any shares of capital stock of the Company or any securities
convertible into or exchangeable for such shares. The Company is not a party to
any agreement or understanding and, to the best of the Company's knowledge,
except as set forth on Schedule 2.4, there is no agreement or understanding
between any persons and/or entities, which affects or relates to the voting or
giving of written consents with respect to any security.

                  12.5 Valid Issuance of the Securities. The Preferred Shares
when issued, sold and delivered to the Purchaser in accordance with this
Agreement will be duly and validly issued, fully paid and non-assessable, and
will be free of restrictions on transfer other than restrictions on transfer
under this Agreement and the Registration Rights Agreement and under applicable
state and federal securities laws. The Conversion Shares issuable upon
conversion of the Preferred Shares have been duly and validly reserved for
issuance and, upon issuance in accordance with the terms of the Designation,
will be duly and validly issued, fully paid and not assessable, and will be free
of restrictions on transfer other than restrictions on transfer under this
Agreement and the Registration Rights Agreement and under applicable state and
federal securities laws. There are no New Jersey State or city taxes or other
charges payable in connection with the execution or delivery of the Company
Agreements or the Preferred Shares or the Conversion Shares.

            12.6 Consents and Approvals. Except for filings under Federal and
applicable state securities laws, no permit, consent, approval or authorization
of, or declaration to or filing with, any federal, state, local or foreign
governmental or regulatory authority or other person, not made or obtained,
other than the filing with, and approval of, the NASDAQ National Market System
("NASDAQ") with respect to the listing of the Conversion Shares and the filing
of any registration statement which may be filed pursuant to the Registration
Rights Agreement, is required in connection with the execution or delivery of
this Agreement or any Company Agreement by the Company, the offer, issuance,
sale or delivery of the Preferred Shares or the Conversion Shares, or the
carrying out by the Company of the other transactions contemplated hereby. The
issuance and sale by the Company of the Preferred Shares, as contemplated
hereby, will not require compliance with the notification or other requirements
of the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, and the
rules and regulations promulgated thereunder, nor require any action by or
approval of the Company's shareholders as such or of any other individual or
entity which has not already been obtained.

                                Ex.4.4 - Page 4
<PAGE>

            12.7 Certificate of Incorporation and By-Laws. The copies of the
Company's Certificate of Incorporation, as amended, and By-Laws, as amended, in
the form made available to the Purchaser are true and correct copies of such
documents and are in full force and effect.

            12.8 SEC Filings. The Company has delivered to the Purchaser, or has
made available, prior to the date hereof true and correct copies of its Annual
Report on Form 10-KSB for its year ended December 31, 2000, its Quarterly Report
on Form 10-QSB for the quarter ended March 31, 2001, its Quarterly Report on
Form 10-QSB for the quarter ended June 30, 2001, each as filed with the
Securities and Exchange Commission (the "SEC") and any and all schedules
attached thereto. . All documents described in this Section 2.8 are hereinafter
referred to as the "Company Reports." The Company has made all filings required
to be made by it under the Securities Act, the Exchange Act and the securities
laws of any state, and any rules and regulations promulgated thereunder. The
Company Reports and other documents filed with the SEC pursuant to the Exchange
Act conformed in all material respects to the requirements of the Exchange Act
and the rules and regulations of the SEC thereunder, and none of such documents
contained any untrue statement of material fact or omitted to state a material
fact necessary to make the statements made therein, in light of the
circumstances under which they were made, not misleading. The Company is
currently eligible to utilize a registration statement on Form S-3 with respect
to the registration of the Registrable Securities (as defined in the
Registration Rights Agreement) required by Section 1.2 of the Registration
Rights Agreement contemplated by Section 4.8 hereof.

            12.9 Litigation. Except as set forth in the Company Reports, there
is no pending or, to the knowledge of the Company, threatened suit, action or
litigation, or administrative, arbitration or other proceeding or governmental
inquiry or investigation questioning the validity of this Agreement, any other
Company Agreement or the transactions contemplated hereby or thereby, or
affecting in any material adverse respect the Company and its subsidiaries,
taken as a whole.

            12.10 Compliance with Laws. The Company and each subsidiary is in
compliance with all laws, ordinances, rules and regulations of governmental
authorities applicable to or affecting it, its properties or its business,
except where non-compliance would not have a material adverse effect on the
business, properties, assets, operations or condition (financial or otherwise)
of the Company and its subsidiaries taken as a whole, and neither the Company
nor any subsidiary has received written notice of any claimed default with
respect to such laws, ordinances, rules and regulations.

            12.11 Financial Statements.

                  (a) (i) The audited consolidated balance sheets and
shareholders' equity of the Company and its subsidiaries as of December 31, 2000
and 1999, (ii) the audited consolidated statements of income and cash flow of
the Company and its subsidiaries, for the two years ended December 31, 2000 and
1999, (iii) the unaudited consolidated balance sheet of the Company and its
subsidiaries as of June 30, 2001, and (iv) the unaudited consolidated statements
of income and cash flows for the period ended June 30, 2001, together with the
notes thereto, copies of all of which have been furnished to the Purchaser, or
have been made

                                Ex.4.4 - Page 5
<PAGE>

available, in each case, present fairly in all material respects the
consolidated financial position of the Company and its subsidiaries at such
dates and the consolidated results of their operations and their consolidated
cash flows for the periods then ended, in conformity with generally accepted
accounting principles, consistently applied ("GAAP"). The audited consolidated
balance sheet dated December 31, 2000 is referred to herein as the "Balance
Sheet".

(b) Except as set forth on Schedule 2.11(b) attached hereto, since December 31,
2000 (the "Balance Sheet Date"), there has not been:

                  (i) any change in the assets, liabilities, financial condition
or operating results of the Company from that reflected in the Balance Sheet and
except changes in the ordinary course of business;

                              (ii) any damage, destruction or loss, whether or
                        not covered by insurance, materially and adversely
                        affecting the assets, properties, financial condition,
                        operating results, prospects or business of the Company
                        (as such business is presently conducted and as it is
                        proposed to be conducted);

                              (iii) any waiver by the Company of a valuable
                        right or of a material debt owed to it;

                              (iv) any satisfaction or discharge of any lien,
                        claim or encumbrance or payment of any obligation by the
                        Company, except in the ordinary course of business and
                        that is not material to the assets, properties,
                        financial condition, operating results or business of
                        the Company (as such business is presently conducted and
                        as it is proposed to be conducted);

                              (v) any material change or amendment to a material
                        contract or arrangement by which the Company or any of
                        its assets or properties is bound or subject;

                              (vi) any material change in any compensation
                        arrangement or agreement with any employee;

                              (vii) any sale, assignment or transfer of any
                        patents, trademarks, copyrights, trade secrets or other
                        intangible assets;

                              (viii) any resignation or termination of
                        employment of any key officer of the Company; and the
                        Company, to the best of its knowledge, does not know of
                        the impending resignation or termination of employment
                        of any such officer;

                              (ix) any mortgage, pledge, transfer of a security
                        interest in, or lien, created by the Company, with
                        respect to any of its material properties or assets,
                        except liens for taxes not yet due or payable;

                                Ex.4.4 - Page 6
<PAGE>

                              (x) any loans or guarantees made by the Company to
                        or for the benefit of its employees, officers or
                        directors, or any members of their immediate families,
                        other than travel advances and other advances made in
                        the ordinary course of its business;

                              (xi) any declaration, setting aside or payment or
                        other distribution in respect of any of the Company's
                        capital stock, or any direct or indirect redemption,
                        purchase or other acquisition of any of such stock by
                        the Company;

                              (xii) to the best of the Company's knowledge, any
                        other event or condition of any character that might
                        materially and adversely affect the assets, properties,
                        financial condition, operating results or business of
                        the Company (as such business is presently conducted and
                        as it is proposed to be conducted); or

                              (xiii) any agreement or commitment by the Company
                        to do any of the things described in this Section
                        2.11(b).

            12.12 Assets. The Company and each subsidiary has good and
marketable title to all of the real and personal properties and assets reflected
on the Balance Sheet as being owned by the Company or such subsidiary at the
Balance Sheet Date, except for properties and assets sold or otherwise disposed
of in the ordinary course of business since the Balance Sheet Date or that are
not material to its business.

            12.13 Tax Matters. The Company and each subsidiary has filed all
U.S. Federal, state, local, foreign and other tax returns which were required to
be filed on or before the date hereof and has paid all taxes which have become
due and payable. All such reports and returns (copies of which have been made
available to the Purchaser) were materially accurate and complete when filed and
reflect all taxes required to be paid by the Company and its subsidiaries for
the periods reported therein.

            12.14 Patents, Trademarks, Proprietary Rights.

                  (a) Each of the Company and its subsidiaries owns or has the
right to use all of the Intellectual Property Rights (as defined below), except
where such failure would not have a material adverse effect on the business,
properties or assets of the Company and its subsidiaries, taken as a whole. For
purposes of this Agreement, "Intellectual Property Rights" means all patents,
copyrights, trademarks, service marks, trade names, permits, trade secrets,
computer programs, software designs and related materials and other intellectual
property that are used by the Company or a subsidiary and are material to the
conduct of the Company's or a subsidiary's business.

                  (b) To the Company's knowledge, the Company's and each
subsidiary's use and enjoyment of the Intellectual Property Rights do not
violate any license or conflict with or infringe the intellectual property
rights of others in a manner which would materially and adversely affect the
business, assets, properties, operations or condition (financial or otherwise)
of the Company and its subsidiaries, taken as a whole. There are no outstanding

                                Ex.4.4 - Page 7
<PAGE>

options, licenses, or agreements of any kind relating to the transfer or
disposition of any of the foregoing, nor is the Company bound by or a party to
any options, licenses or agreements of any kind relating to the transfer or
disposition of any of its Intellectual Property Rights. The Company has not
received any communications alleging that the Company has violated or, by
conducting its business as proposed, would violate any of the patents,
trademarks, service marks, trade names, copyrights or trade secrets or other
proprietary rights of any other person or entity. The Company is not aware that
any of its employees is obligated under any contract (including licenses,
covenants or commitments of any nature) or other agreement, or subject to any
judgment, decree or order of any court or administrative agency, that would
interfere with the use of his or her best efforts to promote the interests of
the Company or that would conflict with the Company's business as proposed to be
conducted. Neither the execution nor delivery of this Agreement or the
Registration Rights Agreement, nor the carrying on of the Company's business by
the employees of the Company, nor the conduct of the Company's business as
proposed, will, to the best of the Company's knowledge, conflict with or result
in a breach of the terms, conditions or provisions of, or constitute a default
under, any contract, covenant or instrument under which any of such employees is
now obligated. The Company does not believe it is or will be necessary to
utilize any inventions of any of its employees (or people it currently intends
to hire) made prior to their employment by the Company or for which the Company
has not received an assignment.

            12.15 Insurance. The Company and its subsidiaries are, and at all
times during the past two years have been, insured with reputable insurers
against all risks customarily insured against by companies in similar lines of
business and all of the insurance policies and bonds required to be maintained
by the Company and its subsidiaries are in full force and effect.

            12.16 Use of Proceeds. The proceeds from the sale of the Preferred
Shares will be used by the Company for working capital purposes including,
without limitation, research and development expenses.

            12.17 Environmental Compliance.

                  (a) Neither the Company nor any subsidiary has generated,
stored, treated, discharged or disposed of any hazardous substances or hazardous
waste in violation of any applicable law or regulation, nor is the Company or
any subsidiary aware of any allegations that any such violations have occurred.
Neither the Company nor any subsidiary is aware of any claims, investigations,
litigation or administrative proceedings, whether actual or threatened, against
the Company or any subsidiary relating to any environmental contamination of any
property owned, used or leased by any of them or arising out of any alleged
violation of any environmental law or regulation.

                  (b) To the Company's knowledge, none of the real property
owned and/or occupied by the Company or any subsidiary has ever been used by
previous owners and/or operators to generate, manufacture, refine, transport,
treat, store, handle or dispose of "Hazardous Substances" or "Hazardous wastes,"
as such terms are defined in the Comprehensive Environmental Response,
Compensation and Liability Act, 42 U.S.C. 9601, et seq., the Resource
Conservation and Recovery Act, 42 U.S.C. 6901, et seq., or applicable state and
local laws, or any regulations issued under any such laws.

                                Ex.4.4 - Page 8
<PAGE>

            12.18 Minute Books. The minute books of the Company and its
subsidiaries heretofore made available for inspection by the Purchaser contain
summaries of all meetings of directors and shareholders since the incorporation
of the Company or such subsidiary, as applicable, and reflect accurately in all
material respects all transactions referred to in such minutes or records.

            12.19 Labor Agreements and Actions. Neither the Company nor any
subsidiary thereof is bound by or subject to, any written or oral, express or
implied, contract, commitment or arrangement with any labor union, and no labor
union has requested or, to the knowledge of the Company, has sought to represent
any of the employees, representatives or agents of the Company or any such
subsidiary thereof. There is no strike or other labor dispute involving the
Company or any subsidiary thereof pending, or to the knowledge of the Company
threatened, which could have a material adverse effect on the business, assets,
properties, operations or condition (financial or otherwise) of the Company and
its subsidiaries, taken as a whole, nor is the Company aware of any labor
organization activity involving any of the employees of the Company or any
subsidiary thereof.

            12.20 Company Status. The Company has registered its Common Stock
pursuant to Section 12(g) of the Exchange Act, is in full compliance with all
reporting requirements of the Exchange Act, and the Company has maintained all
requirements for the continued listing of its Common Stock on NASDAQ, and such
Common Stock is currently listed and traded on NASDAQ.

            12.21 No "Directed Selling Efforts" or "General Solicitation" in
Regard to this Transaction. The offer to sell the Preferred Shares and the
Conversion Shares issuable upon conversion of Preferred Shares was directly
communicated to the Purchaser. At no time was the Purchaser presented with or
solicited by any leaflet, newspaper or magazine article, radio or television
advertisement or any other form of general advertising or solicited or invited
to attend a promotional meeting otherwise than in connection and concurrently
with such communicated offer. The Company has not conducted any "general
solicitation" (as that term is used in Regulation D) with respect to the
Preferred Shares, nor has it made any offers or sales of the Preferred Shares or
solicited any offers to buy the Preferred Shares, under circumstances that would
require registration of the Preferred Shares under the Securities Act.

            12.22 Third Party Consents; Business Not in Violation. The Company
has obtained from third parties all consents necessary to consummate the
transactions contemplated hereby and by the other Company Agreements. The
business of the Company and its subsidiaries is not being conducted in violation
of any law, ordinance or regulations of any governmental entity, except for
violations or potential violations which either individually or in the aggregate
do not and will not have a material adverse effect on the Company and the
subsidiaries business, properties, assets, operations or condition (financial or
otherwise) taken as a whole.

            12.23 Investment Company. The Company is not, and is not controlled
by or under common control with an affiliate of, an "investment company" within
the meaning of the Investment Company Act of 1940, as amended.

                                Ex.4.4 - Page 9
<PAGE>

            12.24 Permits. Each of the Company and its subsidiaries possesses
all franchises, certificates, licenses, authorizations and permits or similar
authority necessary to conduct its business as described in the Company Reports
except where the failure to possess such permits would not, individually or in
the aggregate, have a material adverse effect on the Company or its
subsidiaries, or their businesses, properties, assets, operations or condition
(financial or otherwise) taken as a whole ("Material Permits"), and neither the
Company nor any such subsidiary has received any notice of proceedings relating
to the revocation or modification of any Material Permit.

            12.25 Company Board of Director Action. The Board of Directors of
the Company at a meeting duly called and held has, by the requisite vote of all
directors present, determined that the issuance and sale of Preferred Shares and
the Conversion Shares issuable upon conversion of Preferred Shares to the
Purchaser pursuant to this Agreement is advisable and in the best interests of
the Company and its shareholders.

            12.26 Full Disclosure. The representations and warranties of the
Company set forth in this Agreement do not contain any untrue statement of a
material fact or omit any material fact necessary to make the statements
contained herein, in the light of the circumstances under which they were made,
not misleading.

            12.27 Regulatory Issues. The Company has received a "warning
letter," dated July 10, 2001, from the U.S. Food and Drug Administration (the
"Warning Letter"). The Company has contacted the FDA and has provided a response
to the Warning Letter by letter dated August 2, 2001 (the "Response Letter").
The Company has taken all corrective actions it deems necessary to address the
issues raised in the Warning Letter and has communicated this to the FDA in its
Response Letter. The information contained in the Response Letter is true and
correct on the date hereof and the Response Letter contains no statements
intended to be misleading. The Company will use its best efforts to resolve any
new or remaining Warning Letter issues in a timely manner should any such issues
be raised by the FDA in its follow-up audit. All other documentation,
correspondence, data, analyses and certificates relating to or regarding any
medical devices of the Company or any of its subsidiaries filed or delivered by
or on behalf of the Company or any subsidiary for any governmental authority,
agency or body were true and correct when so filed or delivered.

      SECTION 13. REPRESENTATIONS AND WARRANTIES OF THE PURCHASER

      The Purchaser understands that the sale to the Purchaser of the Preferred
Shares will not be registered under the Securities Act, on the grounds that the
sale is exempt pursuant to Regulation S of the Securities Act or Section 4(2) of
the Securities Act and/or Regulation D promulgated under Section 4(2) of the
Securities Act, and that the reliance of the Company on such exemptions is
predicated in part on the Purchaser's representations, warranties, covenants and
acknowledgments set forth in this Section 3.

            13.1 Organization and Standing of Purchaser; Principal Place of
Business. The Purchaser is a corporation duly incorporated or organized, validly
existing and in good standing under the laws of Minnesota and was not formed for
the specific purpose of acquiring the

                                Ex.4.4 - Page 10
<PAGE>

Preferred Shares or the Conversion Shares. The Purchaser's principal place of
business is as set forth in the notice provision contained in Section 10.5
hereof.

            13.2 Purchase Without View to Distribution. Without limiting the
Purchaser's right to sell the Preferred Shares or the Conversion Shares pursuant
to a registration statement or an exemption from registration, the Purchaser
represents and warrants to the Company that the Preferred Shares and the
Conversion Shares to be purchased by it are being acquired by the Purchaser for
its own account for investment only, not as a nominee or agent, and not with a
view to resale or distribution thereof within the meaning of the Securities Act,
and the rules and regulations thereunder, and the Purchaser will not, directly
or indirectly, offer, sell, pledge, transfer or otherwise dispose of the
Preferred Shares or the Conversion Shares in violation of the Securities Act or
any applicable state securities laws.

            13.3 Restrictions on Transfer. The Purchaser (i) acknowledges that
the Preferred Shares and the Conversion Shares are "Restricted Securities" under
the Federal securities laws and are not registered under the Securities Act,
(ii) acknowledges that the Preferred Shares and the Conversion Shares must be
held indefinitely by it unless they are subsequently registered under the
Securities Act or an exemption from registration is available, (iii) is aware
that any routine sales under Rule 144 under the Securities Act of any such
shares may be made only in limited amounts and in accordance with the terms and
conditions of that Rule and that in such cases where the Rule is not applicable,
compliance with some other registration exemption will be required, (iv) is
aware that Rule 144 is not presently available for use by the Purchaser for
resale and (v) is aware that, except as set forth in the Registration Rights
Agreement, the Company is not obligated to register under the Securities Act any
sale, transfer or other disposition of the Preferred Shares or the Conversion
Shares.

            13.4 Access to Information. The Purchaser confirms that the Company
has made available to it the opportunity to ask questions of and receive answers
from the Company's officers and directors concerning the terms and conditions of
the offering and the business and financial condition of the Company and its
subsidiaries, , and the Purchaser has received, such additional information, in
addition to that set forth herein, about the business and financial condition of
the Company and its subsidiaries and the terms and conditions of the offering as
it has requested.

            13.5 Additional Representations of the Purchaser. The Purchaser
represents and warrants that (i) it is an "accredited investor" as such term is
defined in Rule 501 promulgated under the Securities Act, (ii) it understands
that an investment in the Preferred Shares and the Conversion Shares involves a
high degree of risk and its financial situation is such that it can afford to
bear the economic risk of holding the Preferred Shares and/or the Conversion
Shares for an indefinite period of time and suffer complete loss of its
investment in the Preferred Shares and the Conversion Shares, (iii) its
knowledge and experience in financial and business matters are such that it is
capable of evaluating the merits and risks of its purchase of the Preferred
Shares and the Conversion Shares as contemplated by this Agreement, (iv) it did
not subscribe for the Preferred Shares or the Conversion Shares as a result of
or subsequent to any advertisement, article, notice or other similar media or
broadcast over television or radio; (v) as of the date hereof, neither the
Purchaser nor any of its agents or affiliates holds a short position in the
Common Stock of the Company; (vi) it has all requisite power and authority to

                                Ex.4.4 - Page 11
<PAGE>

execute, deliver and perform this Agreement, (vii) the purchase of the Preferred
Shares and the Conversion Shares by it has been duly and properly authorized and
this Agreement has been duly executed and delivered by it or on its behalf and
constitutes the valid and binding obligation of the Purchaser, and is
enforceable against the Purchaser in accordance with its terms, and (viii) it
has no contract, arrangement or understanding with any broker, finder of similar
agent with respect to the transactions contemplated by this Agreement.

            13.6 Legends. The Purchaser understands that the certificates
evidencing the Preferred Shares shall bear the legend set forth in Section 8.2
herein.

      SECTION 14. CONDITIONS PRECEDENT TO PURCHASER'S OBLIGATIONS

      The Purchaser's obligation to purchase and make payment for the Preferred
Shares subscribed for hereunder by it on the Closing Date is subject, at its
option, to the satisfaction of each of the following conditions:

            14.1 Representations and Warranties. On the Closing Date, the
representations and warranties contained in Section 2 hereof shall be true and
correct in all material respects with the same effect as though made on and as
of the Closing Date, and the Company shall have so certified to the Purchaser in
writing.

            14.2 Performance. All the covenants, agreements and conditions
contained in this Agreement to be performed or complied with by the Company on
or prior to the Closing Date shall have been performed or complied with in all
material respects, and the Company shall have so certified to the Purchaser in
writing.

            14.3 Designation. The Company shall have adopted and filed with the
Secretary of State of the State of New Jersey the Designation.

            14.4 Opinion of Counsel to the Company. On the Closing Date, the
Purchaser shall have received an opinion from counsel for the Company, dated the
Closing Date, which shall be in a form reasonably acceptable to the parties.

            14.5 Proceedings; Certified Copies. All proceedings to be taken in
connection with the transactions contemplated by this Agreement to be
consummated on or prior to the Closing Date, and all documents incident thereto,
shall be satisfactory in form and substance to the Purchaser. The Purchaser
shall have received such certified copies or other copies of such documents as
they may reasonably request.

            14.6 No Proceeding or Litigation. No suit, action, or other
proceeding seeking to restrain, prevent or change the transactions contemplated
hereby or otherwise questioning the validity or legality of such transactions
shall have been instituted and be pending.

            14.7 No Material Adverse Change. There shall have been no material
adverse change since the Balance Sheet Date, except as set forth on Schedule
2.11(b) attached hereto, in the business, properties, assets, operations, or
condition (financial or otherwise) of the Company and its subsidiaries, taken as
a whole, and the Company shall have so certified to the Purchaser in writing.

                                Ex.4.4 - Page 12
<PAGE>

            14.8 Registration Rights Agreement. The Company shall have executed
and delivered a Registration Rights Agreement in the form attached hereto as
Exhibit B.

            14.9 NASDAQ Listing. The Company shall have given or made all
notices or filings with the National Association of Securities Dealers, Inc.
(the "NASD") and shall have complied with all rules and regulations of the NASD
required in connection with the transactions contemplated hereby.

            14.10 Investment by Century Medical, Inc. The Company shall have
provided to the Purchaser, by facsimile transmission, a copy of the Century
Medical Agreement executed by the Company and Century Medical, Inc. including
copies of all signature pages thereto, which agreement shall provide (i) an
obligation by Century Medical, Inc. to purchase shares of Series A Preferred
Stock having an aggregate value of at least $1,200,000, and (ii) that the
closing of such purchase shall occur substantially concurrently with the
purchase and sale contemplated hereunder.

            14.11 Fusion Capital Investment. The Securities and Exchange
Commission shall have declared effective the registration statement with respect
to shares of the Company's Common Stock to be sold by Fusion Capital Fund II,
LLC ("Fusion Capital") as contemplated in the Common Stock Purchase Agreement,
dated as of June 11, 2001, entered into between the Company and Fusion Capital
and all other conditions precedent to the investment by Fusion Capital shall
have been satisfied.

      SECTION 15. CONDITIONS PRECEDENT TO THE COMPANY'S OBLIGATIONS

      The Company's obligation to sell the Preferred Shares subscribed for by
the Purchaser on the Closing Date is subject, at the Company's option, to the
satisfaction of each of the following conditions:

            15.1 Representations and Warranties. On the Closing Date, the
representations and warranties contained in Section 3 hereof shall be true and
correct in all material respects with the same effect as though made on and as
of the Closing Date and the Purchaser shall have so certified to the Company in
writing.

            15.2 Performance. All the covenants, agreements and conditions
contained in this Agreement to be performed or complied with by the Purchaser on
or prior to the Closing Date shall have been performed or complied with in all
material respects, and the Purchaser shall have so certified to the Company in
writing.

            15.3 No Proceeding or Litigation. No suit, action, or other
proceeding seeking to restrain, prevent or change the transactions contemplated
hereby or otherwise questioning the validity or legality of such transactions
shall have been instituted and be pending.

      SECTION 16. COVENANTS OF THE COMPANY PRIOR TO CLOSING

            16.1 Operation of Business in Ordinary Course. Prior to the Closing,
the Company and each subsidiary will operate its business only in the usual and
normal course.

                                Ex.4.4 - Page 13
<PAGE>

            16.2 Conditions Precedent. The Company and the Purchaser shall use
their best efforts to cause the conditions specified in Sections 4 and 5 to be
satisfied by the Closing Date.

      SECTION 17. COVENANTS OF THE PARTIES AFTER CLOSING

            17.1 Reporting Status. So long as the Purchaser beneficially owns
any Preferred Shares or Conversion Shares, the Company covenants that it shall
use its best efforts to file all reports required to be filed with the SEC
pursuant to Section 13 or 15(d) of the Exchange Act, and the Company shall not
terminate its status as an issuer required to file reports under the Exchange
Act.

            17.2 Reservation of Common Stock. The Company shall at all times
reserve and keep available out of its authorized but unissued shares of Common
Stock, solely for the purposes of issuance upon conversion of Preferred Shares,
such number of shares of Common Stock as are equal to the Conversion Shares
issuable upon conversion of the outstanding Preferred Shares. All shares of
Common Stock which are so issuable shall, when issued, be duly and validly
issued, fully paid and nonassessable.

      SECTION 18. COMPLIANCE WITH SECURITIES ACT; RESTRICTIONS ON
TRANSFERABILITY

            18.1 Compliance with Securities Act. The Preferred Shares and the
Conversion Shares shall not be transferable, except upon the conditions
specified in this Section 8, which conditions are intended to insure compliance
with the provisions of the Securities Act and applicable state securities laws
in respect of any such transfer.

            18.2 Restrictive Legend. Each certificate representing the Preferred
Shares and Conversion Shares issued upon conversion of the Preferred Shares
shall (unless otherwise permitted by the provisions of Section 8.4 below) be
stamped or otherwise imprinted with the following legend:

            "THE PREFERRED SHARES REPRESENTED BY THIS CERTIFICATE AND THE SHARES
            OF COMMON STOCK ISSUABLE UPON CONVERSION OF THESE PREFERRED SHARES
            HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
            AMENDED (THE "ACT"), OR ANY APPLICABLE STATE SECURITIES LAW AND THE
            MAY NOT BE OFFERED, SOLD, TRANSFERRED, PLEDGED OR OTHERWISE DISPOSED
            OF EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT FOR THE
            SECURITIES UNDER THE ACT AND APPLICABLE STATE SECURITIES LAWS OR
            PURSUANT TO AN OPINION OF COUNSEL ACCEPTABLE TO THE COMPANY THAT
            SUCH REGISTRATION IS NOT REQUIRED. HEDGING TRANSACTIONS INVOLVING
            THESE SHARES MAY NOT BE CONDUCTED UNLESS IN COMPLIANCE WITH THE

                                Ex.4.4 - Page 14
<PAGE>

            ACT. THE HOLDER OF THIS CERTIFICATE IS SUBJECT TO, AND A BENEFICIARY
            OF, CERTAIN PROVISISONS SET FORTH IN A PREFERRED STOCK PURCHASE
            AGREEMENT, DATED AS OF OCTOBER 23, 2001; A COPY OF THE AGREEMENT
            EVIDENCING SUCH TERMS MAY BE OBTAINED FROM THE COMPANY WITHOUT
            CHARGE."

            18.3 Restrictions on Transferability.

                  (a) The Purchaser acknowledges that the Preferred Shares and
the Conversion Shares issuable upon the conversion of the Preferred Shares have
not been registered under the Securities Act and, except as provided in the
Registration Rights Agreement, such shares are not being registered under the
Securities Act and may not be transferred (and the Company shall have the right
to refuse to transfer such securities) unless (i) registered under the
Securities Act or (ii) an exemption from registration exists and the holder of
such shares shall have delivered written notice to the Company describing in
reasonable detail the proposed transfer, together with an opinion of counsel to
the effect that such transfer may be effected without registration of such
shares under the Securities Act, in which event, the holder of the shares being
transferred shall not consummate the transfer until (1) the prospective
transferee has confirmed to the Company in writing its agreement to be bound by
the provisions of this Agreement or (2) such holder shall have delivered to the
Company an opinion of such counsel that no subsequent transfer of such Preferred
Shares or Conversion Shares shall require registration under the Securities Act.
Promptly upon receipt of any opinion described in clause (iii) of the preceding
sentence, the Company shall prepare and deliver in connection with the
consummation of the proposed transfer, new certificates for the Preferred Shares
or Conversion Shares being transferred that do not bear the legend set forth in
Section 8.2.

                  (b) The Purchaser acknowledges that any sale of the Preferred
Shares or the Conversion Shares made in reliance upon Rule 144 promulgated under
the Securities Act may be made only in accordance with the terms of that Rule
and further, if that Rule is not applicable, any resale of the Preferred Shares
or the Conversion Shares under circumstances in which the seller or the person
through whom the sale is made may be deemed to be an underwriter, as such term
is defined in the Securities Act, and may require compliance with some other
exemption under the Securities Act or the rules and regulations of the SEC
thereunder.

            18.4 Restriction on Conversion by the Purchaser. Notwithstanding
anything herein, or in the Designation to the contrary, in no event shall the
Purchaser have the right to convert the Preferred Shares if, as a result of such
conversion, the aggregate number of shares of Common Stock beneficially owned by
the Purchaser and its affiliates would exceed 19.9% of the outstanding shares of
the Common Stock following such exercise. For purposes of this Section 8.4,
beneficial ownership shall be calculated in accordance with Section 13(d) of the
Exchange Act. Nothing in this Section 8.4 shall be deemed to limit or otherwise
affect the Company's right to compel the conversion of the Preferred Shares in
accordance with the provisions of the Designation.

                                Ex.4.4 - Page 15
<PAGE>

      SECTION 19. SURVIVAL OF REPRESENTATIONS AND WARRANTIES

      All representations and warranties made herein and in the certificates
delivered pursuant hereto are made as of the date hereof and shall survive the
execution and delivery of this Agreement and the issuance and sale of the
Preferred Shares hereunder for a period of eighteen months.

      SECTION 20. MISCELLANEOUS

            20.1 Owner of Preferred Shares. The Company may deem and treat the
person in whose name the Preferred Shares are registered as the absolute owner
thereof for all purposes whatsoever, and the Company shall not be affected by
any notice to the contrary.

            20.2 Successors and Assigns. This Agreement shall be binding upon,
shall inure to the benefit of the respective successors, executors, personal
representatives, heirs, and permitted assigns of each of the parties hereto.

            20.3 Broker or Finder. Each party to this Agreement represents and
warrants that, to the best of its knowledge, no broker or finder has acted for
such party in connection with this Agreement or the transactions contemplated by
this Agreement and that no broker or finder is entitled to any broker's or
finder's fee or other commission in respect thereof based in any way on
agreements, arrangements or understandings made by such party. The Company shall
indemnify the Purchaser against, and hold it harmless from, any liability, cost,
or expense (including reasonable attorneys' fees and expenses) resulting from
any agreement, arrangement, or understanding made by the Company, and the
Purchaser shall indemnity the Company against, and hold the Company harmless
from, any liability, cost, or expense (including reasonable attorneys' fees and
expenses) resulting from any agreement, arrangement, or understanding made by
the Purchaser with any third party, for brokerage or finder's fees or other
commissions in connection with this Agreement or any of the transactions
contemplated hereby.

            20.4 Governing Law. This Agreement shall be governed by and
construed and enforced in accordance with the laws of the State of New Jersey,
without regard to conflicts of law principles.

            20.5 Notice. Any notice or other communications required or
permitted hereunder shall be deemed given when delivered personally, or upon
receipt by the party entitled to receive the notice when sent by registered or
certified mail, postage prepaid, or by a recognized national overnight courier
service addressed as follows or to such other address or addresses as may
hereafter be furnished in writing by notice similarly given by one party to the
other:

         To the Company:     EP MedSystems, Inc.
                             100 Stierli Court, Suite 107
                             Mount Arlington, NJ  07856
                             Attention:  David Jenkins, Chief Executive Officer

                                Ex.4.4 - Page 16
<PAGE>

         To the Purchaser:   Medtronic, Inc.
                             710 Medtronic Parkway NE
                             Minneapolis, MN 55432-5604

                             with separate copies thereof addressed to

                             Attention:   General Counsel
                                          Mail Stop LC400
                                          Telecopier No.: (763) 572-5459

                             and

                             Attention:   Vice President and Chief
                                          Development Officer
                                          Mail Stop LC390
                                          Telecopier No.: (763) 505-2542

Notice to any holder of Preferred Shares other than the Purchaser shall be given
in a like manner to such holder at the address reflected in the Company's
records.

            20.6 Full Agreement. This Agreement and the Exhibits and Schedules
attached hereto or delivered herewith, and any other documents delivered
herewith, sets forth the entire understanding of the parties with respect to the
transactions contemplated hereby.

            20.7 Disclosure/Publicity. The parties acknowledge and agree that
the Company shall make public disclosure with the SEC and otherwise as
appropriate describing the terms of the transaction consummated at closing.

            20.8 Headings. The headings of the sections of this Agreement are
inserted for convenience of reference only and shall not be considered a part
hereof.

            20.9 Amendment. This Agreement may be modified, amended or changed
only by a written instrument executed by the Company and the Purchaser.

            20.10 Schedules and Exhibits. Disclosure of any fact or item in any
Schedule or Exhibit hereto referenced by a particular paragraph or section in
this Agreement shall be deemed to be disclosed with respect to any other
paragraph or section (whether or not an explicit cross-reference appears) should
the existence of such fact or item or its contents be relevant to that other
paragraph or section.

            20.11 Counterparts. This Agreement may be executed concurrently in
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument upon delivery, by telefax
or otherwise, of all counterparts to all parties hereto.

                            [Signature Page Follows]

                                Ex.4.4 - Page 17
<PAGE>

      IN WITNESS WHEREOF, each of the parties hereto has fully executed this
Agreement on the date first set forth above.

                             EP MEDSYSTEMS, INC.

                             By: s/ David A. Jenkins
                             Name: David A. Jenkins
                             Title: Chief Executive Officer

                             MEDTRONIC, INC.

                             By: s/ Michael D. Ellwein
                             Name: Michael D. Ellwein
                             Title: Vice President and Chief Development Officer

                                Ex.4.4 - Page 18
<PAGE>

                                  Schedule 2.4

                          Capital Stock of the Company

      David Jenkins, the Company's Chairman of the Board and Chief Executive
Officer, is a shareholder of the Company owning stock directly and through his
50% ownership interest in Cardiac Capital, LLC. Mr. Jenkins is a party to a
letter agreement with Rollins Investment Fund, the other 50% owner of Cardiac
Capital, LLC, pursuant to which Mr. Jenkins has agreed that he shall forebear
from selling any shares of common stock of the Company owned by him and shall
cause his spouse, lineal descendants and any trust for the benefit of any of
them to similarly forebear from selling any shares of common stock of the
Company owned by any of them in the first year following the closing of the
private placement financing in which Cardiac Capital, LLC purchased its shares
(i.e. the period from March 28, 2001 through March 27, 2002) without the prior
written consent of the Rollins Investment Fund. The agreement further provides
that, notwithstanding any provision to the contrary contained in the Operating
Agreement of Cardiac Capital, LLC, the decision of Cardiac Capital to exercise
its registration rights after the first anniversary of the closing may be made
by Rollins Investment Fund in its sole judgment without the consent of Mr.
Jenkins.

                                Ex.4.4 - Page 19
<PAGE>

                                Schedule 2.11(b)
                         Changes Since December 31, 2000

      (vi) The Company has not made any material change to an agreement with any
employee but has entered into an employment agreement with a new employee,
Reinhard Schmidt, which agreement has not been previously disclosed. Mr. Schmidt
was also appointed to the Company's Board of Directors as of August 25, 2001.

      (x) In connection with his new employment with the Company, Mr. Schmidt
purchased 100,000 shares of the Company's common stock borrowing $220,000 from
the Company in order to effect the purchase. The promissory note is secured by a
pledge of the shares so purchased.

      (xii) The Company's cash position as of June 30, 2001 was approximately
$1,482,000. Also, the Company received a "warning letter" from the U.S. Food and
Drug Administration on July 10, 2001, following a recent inspection. The letter
requires the Company to investigate and correct various observations made by the
FDA with respect to the Company's facilities and procedures including those
relating to its quality assurance systems. By correspondence, dated August 2,
2001, as well as by telephonic communications, the Company has responded to the
"warning letter", has received an acknowledgment letter from the FDA, dated
September 17, 2001, and is awaiting reinspection.

                                Ex.4.4 - Page 20

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00031-of-00352.parquet"}]]